Good MorningEquities slipped again on Wednesday with the FOMC’s Beige Book in the market’s focus. The Beige Book revealed improving conditions but also a growing uncertainty spurred by the resurgence of COVID-19 as well as mounting inflation. The key takeaway from the report is that the FOMC is still on track to begin tapering sometime this year.
The market may get another clue as to when that will happen on Friday with the release of the PPI data. The consensus is for producer price increases to moderate from a 1.0% monthly gain posted in August to a slower 0.6% gain in September. Even so, producer level inflation is rising quickly and will lead to higher consumer prices down the road. If the PPI comes in hotter than expected the FOMC could begin the taper as soon as the September meeting in two weeks’ time.
Featured: Before you take your next trade – open here. (Ad) 
|
Consumer Staples | | The concept of passive income is certainly attractive on paper, as it involves generating regular money flows with minimal activity. However, creating a reliable passive income source is easier said than done. Some people look to business activities or real estate rental income to generate steady st... Read the Full Story |
|
From Our Partners | | The federal government is throwing its full support behind a new class of AI technology, in what's being called the biggest push since the Apollo moon landing.
This AI reportedly works 10,000 times faster than human PhDs and could eventually be worth 500 times more than ChatGPT. Elon Musk has called the underlying tech the most disruptive force in history. | | Discover the stock positioned to benefit as this AI initiative accelerates |
|
Consumer Discretionary | |
If you happened to hold Kirkland’s (NASDAQ: KIRK) stock throughout all of last year, you enjoyed a mind-blowing 1,342% return. The home décor retailer was among the top 10 U.S. stock performers in 2020 thanks to pandemic-driven shopping habits and Kirkland’s strengthened competi... Read the Full Story |
|
Markets | |
Index funds are a curious thing.
On the one hand, plenty of long-term investors swear by them as a way of automating retirement investing and creating an allocated portfolio.
On the other hand, some investors correctly point out that an over-reliance on index funds can limit other investment o... Read the Full Story |
|
From Our Partners | | Billionaires are quietly preparing for what comes next - stockpiling gold, guns, and gas masks. TradeSmith CEO Keith Kaplan says there is a bigger story behind the headlines.
After spending 17 million dollars on AI research and enlisting a former NSA codebreaker and Pentagon insider, Kaplan's team has identified a different way to approach AI investing, one that skips Nvidia, SpaceX, and the Magnificent Seven entirely. | | See Keith Kaplan's full AI research before August 31 |
|
Healthcare | | Baby monitor and products maker Owlet (NYSE: OWLT) stock has been pummeled so far in 2021. Most recently shares collapsed over (-20%) to all-time lows on new that the SEC has allowed warrant holders to exercise their options. This could lead to an additional 18.1 million shares to be issued on top o... Read the Full Story |
|
Consumer Discretionary | |
For some traditional investors, it may be easy to dismiss the retail trading community on Reddit. One reason for this is that many Reddit investors use the trading app Robinhood (NASDAQ: HOOD), which is widely seen as a catalyst for the rise in “meme stocks” such as GameStop and AMC En... Read the Full Story |
|
From Our Partners | | Elon Musk quietly filed a document with the federal government tied to artificial intelligence, one of the largest markets in the world.
James Altucher, who previously flagged Nvidia in 2008 and Bitcoin in 2013, says the filing could rival Tesla, SpaceX and xAI combined.
Few investors know this filing exists, but that is expected to change quickly. | | Click here to see details on Elon Musk's newest AI filing |
|
Markets | |
Invest In Cloud Stocks With True Utility
The cloud has long been a driving force of growth within the tech industry and it will remain so long into the future. The problem for investors, if there is one, is that the growth of the cloud has slowed which makes cloud services and cloud-based busines... Read the Full Story |
|
Healthcare | | It’s been a relatively quiet week for IPOs, but as summer transitions into fall, look for that to change.
According to IPO tracker Renaissance Capital, as many as 15 companies may join the public markets in the coming week. These include eyeglass retailer Warby Parker, tech consulting firm T... Read the Full Story |
|
Consumer Discretionary | |
The transition to electric vehicles may take longer than breathlessly imagined at the end of 2020, but it is occurring. The Biden administration still is shooting for an aggressive target. Specifically by 2030, the administration wants 50% of the vehicles sold in the United States to be either bat... Read the Full Story |
|
Finance | | Insurance fintech platform provider Lemonade (NYSE: LMND) stock is turning the corner after recovering from Q1 2021 Texas Freeze. The fintech provides insurance products for home, life, rental, pets, and soon-to-be car. The car insurance is a strong tailwind for the Company as it completed the devel... Read the Full Story |
|
Technology | |
In the week after CrowdStrike Holdings (NASDAQ: CRWD) reported earnings, CRWD stock is down nearly 6% (5.8%). The earnings report was strong with CrowdStrike beating on both earnings and revenue.
Since debuting in June 2019, the stock is up 320%. However, investors have long been concerned abou... Read the Full Story |
|
The Early Bird Stock Of The Day Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis. The company also develops Tumor Treating Fields, a portable device for delivery of electric fields; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Tisotumab vedotin, an antibody drug conjugate; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, and pancreatic cancer; and Bemarituzumab to treat gastric and gastroesophageal junction cancer patients. In addition, it develops Sulbactam/durlobactam, a combination of a beta-lactam antibiotic and a beta-lactamase inhibitor for the treatment of serious infections caused by Acinetobacter; KarXT for the treatment of psychiatric and neurological conditions. It has license and collaboration agreement with Tesaro, Inc. to develop, manufacture, and commercialize niraparib; NovoCure to develop and commercialize Tumor Treating Fields; Deciphera to develop and commercialize ripretinib; Paratek Bermuda Ltd. to develop, manufacture, and commercialize omadacycline; argenx, to develop and commercialize efgartigimod; BMS to develop and commercialize tisotumab vedotin and repotrectinib; Mirati to research, develop, manufacture, and commercialize adagrasib; Amgen to develop and commercialize bemarituzumab; and Innoviva to develop and commercialize Sulbactam-Durlobactam; Karuna to develop and commercialize KarXT. The company was incorporated in 2013 and is headquartered in Shanghai, China. | | View Today's Stock Pick |
|
